Fluge and Mella found increased expression of pyruvate dehydrogenase kinases. They did not show increased activation of pyruvate dehydrogenase kinases.
It goes without saying it is activated by ATP, as that by definition how all kinases work. This is not quite the "increased activation" feedback system you are looking for...
Good point. I guess I may have to concede this one, unless I can find a mechanism by which a translocator protein blockage increases pyruvate dehydrogenase kinase gene expression.
However, if we assume that an inhibited pyruvate dehydrogenase is the only blockage in ME/CFS energy metabolism, that blockage alone would seem unlikely to account for ME/CFS symptoms, as far as I can see (but I may be wrong).
This is because an inhibited pyruvate dehydrogenase will only serve to block the coupling of glycolysis to the mitochondria, and if this coupling is blocked, it means that you will be limited in the ability to process glucose from dietary carbohydrates in an efficient way via the glucose > glycolysis > pyruvate pathway into the mitochondria.
But the failure to efficiently process glucose via the pyruvate pathway into the mitochondria should not lead to an energy shortage, because mitochondria can also process dietary fats and protein as alternative energy sources. As we know, people who undertake a ketogenic diet get nearly all their energy from dietary fats and protein.
When you get your energy from dietary fats and protein, I believe you can bypass the glucose > glycolysis > pyruvate pathway into the mitochondria. Thus this pyruvate pathway could be substantially blocked, but that would not significantly affect the processing of fats and protein in the mitochondria. I think the fats and protein would still be processed with normal efficiency, and you would be able to derive a lot of energy from them.
A ketogenic diet typically contains (ref:
1):
60-75% of calories from fat (or even more)
15-30% of calories from protein
5-10% of calories from carbs
When ketones-adapted runner Zach Bitter completed a 100 mile run in just under 12 hours, data showed that 98 percent of his energy came from fat, and only 2 percent from carbs. Ref:
1
Thus just on fats and proteins, you can function pretty well, and have no symptoms of ME/CFS. In fact you can run 100 miles on more or less just fats!
So how then could a blockage in the pyruvate pathway into the mitochondria cause ME/CFS symptoms? I cannot see that it could, not on its own at least.
(Having said that, some ME/CFS patients do fare well on a ketogenic diet; so maybe in the light of this latest Fluge and Mella finding on pyruvate dehydrogenase inhibition, we might consider trying a ketogenic diet to see if it benefits ME/CFS).
There would have to be some other blockages in the energy metabolism, alongside a pyruvate pathway blockage, if we are going to get the sort of major energy shortage that might underpin ME/CFS.
These other blockages in energy metabolism could include a blockage in oxidative phosphorylation (which the
MBM studies found many ME/CFS patients have), or a translocator protein blockage (which the MBM studies found most ME/CFS patients have).
Note that Myhill et al use the term "translocator protein" to refer to the adenine nucleotide translocator (ANT).
But a pyruvate pathway blockage alone I cannot see causing ME/CFS. (But note that my knowledge of energy metabolism pathways is not very good, so if anyone can see any flaws with the above argument, please do point them out).
It's worth posting
Figure 1 from the MBM 2009 study below, as this nicely shows the inputs and outputs of the mitochondria. Note how the glucose > glycolysis > pyruvate input to the mitochondria is separate to the fatty acids input.
If the ATP translocator had any serious blockage (widespread across many cells), our symptoms would be quite different (along the lines of severe genetic mitochondrial diseases).
I don't think you can predict in advance the symptoms that a mitochondrial translocator protein blockage might produce.
And note that the MBM studies found that the translocator protein in ME/CFS patients is not completely blocked, but partially blocked to varying degrees. The "ATP Profiles" test measures the efficiency of translocator protein functioning, and provides a translocator protein efficiency figure from 0 to 1, which depends on the degree of blockage of the translocator protein (the more efficient, the less the blockage).
If you look at
Figure 2 from the MBM 2009 paper, the TL IN graph gives the efficiency of various ME/CFS patients' translocator protein as it transports ATP from the mitochondria into the cytosol of the cell; and the TL OUT graph gives the efficiency of the translocator protein as it transports ADP out of the cell, and back into the mitochondria.
As you can see from those two graphs, ME/CFS patients have varying translocator protein efficiencies, with some as low as 0.1 (these are the most blocked patients), but others with higher efficiencies of 0.3 or 0.4, etc.